When income matters more than growth, retirees turn to funds that deliver quarterly checks without volatility. The iShares ...
Discover why Mirum Pharmaceuticals, Inc. stock surged 65%. Explore robust pipeline growth, revenue outlook, and analyst ...
HDV yields 3.3% and paid $4.12 per share in 2024 with dividend growth averaging 5-6% annually. Energy comprises 21.9% of the portfolio. This creates significant commodity price exposure. SCHD offers a ...
Stronger fuel standards and cleaner technologies are driving major efficiency gains in China’s heavy-duty vehicle fleet, ...
Dominic has spent a few months with the Sennheiser hd 800 S headphones and the hdv 820 amplifier - a pairing costing around £3,500. Just how good are they? What the Federal Reserve rate cut means for ...
STOCKHOLM, Sweden, December 22, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has signed a non-binding letter of intent (LOI) with Novakand ...
The remaining market showed considerable fragmentation. Hyundai-KIA Automotive held a 11.8% market share, while Vietnamese ...
Clinical Trials Arena on MSN
Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial
Lilly is investigating the triple G agonist retatrutide in seven other Phase III trials, which are due to read out in 2026.
Gilead Sciences, Inc. and Assembly Biosciences, Inc. , today announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus (HSV) helicase-primase ...
The complete 96-week and post-treatment follow up data from the Phase 1 monotherapy (NCT04536337) cohorts in subjects with chronic HBV infection show the continued potential of pevifoscorvir sodium to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results